Intra-Cellular Therapies Overview
Intra-Cellular Therapies (ITCI) has a P/E ratio of -183.15, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-183.15
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ITCI is -183.15. That is below the Healthcare sector average of 24.78. Investors often review this figure alongside Intra-Cellular Therapies's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ITCI currently prints -183.15 for P/E ratio, while the sector average sits near 24.78. That is roughly 839.1% below the sector mean. Large gaps often invite a closer look at Intra-Cellular Therapies's growth, margins, and balance sheet.
A P/E ratio of -183.15 for Intra-Cellular Therapies is not 'good' or 'bad' on its own. Compare it with the peer average (24.78) and with ITCI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ITCI's P/E ratio (-183.15), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Intra-Cellular Therapies's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
